Medasense Biometrics Ltd., a Ramat Gan, Israel-based developer of a proprietary objective pain monitoring technology, closed an $8m Series B financing.
The round was led by Benslie International Ltd., with participation from existing investors and a strategic investor – a global medical technology corporation.
The company intends to use the funds to accelerate commercialization of its flagship product PMD-200™.
Led by Galit Zuckerman, CEO and founder, Medasense provides PMD-200™, an objective pain monitoring system for operating rooms and critical care, where patients under general anesthesia are unable to communicate their pain.
The system consists of a non-invasive finger probe that records multiple pain-related physiological signals, and the PMD-200™ monitor, which uses a composite algorithm to determine an individual’s real-time, pain level index – NoL™.
The technology uses a unique multi-parametric approach and advanced statistical modeling to convert complicated data into a patient’s “Signature of Pain”.